Clinical trials recruiting for Prostate Adenocarcinoma
52
Recruiting trials
50
US states with sites
14
Countries
6%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 17 |
| Illinois | 11 |
| New York | 9 |
| Florida | 6 |
| Oregon | 6 |
| Texas | 6 |
| Maryland | 5 |
| New Jersey | 5 |
| North Carolina | 5 |
| Ohio | 5 |
| Washington | 5 |
| Wisconsin | 5 |
Top cities
Chicago, Illinois 10Los Angeles, California 8New York, New York 7Portland, Oregon 6San Francisco, California 5Seattle, Washington 5Baltimore, Maryland 4Dallas, Texas 4Duarte, California 4Durham, North Carolina 4
Self-screener
Recruiting trials
- A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
- A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
- A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
- ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
- Active Surveillance for Low Risk Prostate Cancer
- An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
- Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
- Customized TULSA-PRO Ablation Registry
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
- Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
- Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
- Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
- Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
- Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
- Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
- High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
- Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
- INSPIRE: INnovative SABR for Prostate Cancer All IREland
- Improving Sexual Quality of Life - Randomized Trial of Two vs Five MRI Guided SABR Treatments for Prostate Cancer
- Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
- MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
- Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
- Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer
- PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
- PSMA PET Response Guided SabR in High Risk Pca
- PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
- Personalized Optimization of Systematic Prostate Biopsy
- Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
- Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
- Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
- Prostatic Size Reduction Following of Leuprorelin Acetate
- Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
- Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
- Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
- Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
- Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
- Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
- Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer
- Two-fraction HDR Monotherapy for Localized Prostate Cancer
- Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression
- rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Related conditions
Trials recruiting for Prostate Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Localized Prostate Carcinoma 21Stage IIIB Prostate Cancer AJCC v8 7Stage III Prostate Cancer AJCC v8 19Stage IIC Prostate Cancer AJCC v8 5Prostate Neoplasm 12Stage IVA Prostate Cancer AJCC v8 13Stage IIIC Prostate Cancer AJCC v8 5Stage IIIA Prostate Cancer AJCC v8 5Stage IIB Prostate Cancer AJCC v8 3
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Prostate Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.